Novel Feeder-Free TIL Expansion Platform Enhances Safety and Efficacy in Immunotherapy

A breakthrough study published in Cancer Biology & Medicine introduces a novel feeder-free protocol for expanding tumor-infiltrating lymphocytes (TILs). By significantly reducing reliance on high-dose interleukin-2 (IL-2), researchers have successfully addressed a critical barrier in adoptive cell therapy. This innovative method preserves T-cell function and limits exhaustion, offering a more sustainable approach to manufacturing potent cellular immunotherapies for various solid malignancies.

The research, conducted by the Chinese PLA General Hospital and Shanghai Juncell Therapeutics, demonstrates that this two-phase expansion system achieves high success rates across diverse tumor types, including melanoma and colorectal cancer. By replacing traditional feeder cells with a precise combination of IL-7, IL-15, and low-concentration IL-2, the protocol generates high-purity TILs with a less exhausted phenotype. These cells exhibit robust cytotoxic activity and superior therapeutic potential in preclinical models.

Furthermore, the study highlights that integrating low-dose PD-1 blockade significantly improves tumor control and treatment tolerability. This combination strategy avoids the severe toxicity associated with systemic high-dose IL-2, potentially paving the way for safer, more accessible clinical applications. These findings represent a major step toward making life-saving TIL-based treatments more scalable and effective for patients battling advanced solid tumors.